E.B. KOMAROVA

Lugansk State Medical University, 1г 50-letiya Oborony Luganska, Lugansk, the Ukraine, 91045

Komarova E.B. — Cand. Med. Sc., Associate Professor of the Department of internal medicine of the faculty of postgraduate education, tel. +380509723993, e-mail: elbelcom@ua.fm

The arthroscopy of knee joint with macro assessment synovial membrane was made in 22 patients with rheumatoid arthritis (RA) before and after the complex treatment. All examined patients in addition to standard therapy received spironolactone 25-50 mg per day for 12 months. Applying of spironolactone in the complex treatment of rheumatoid arthritis reduced inflammatory and villous hyperplasia of the synovial membrane, reduced the presence of fibrin and pannus in the joints of patients with rheumatoid arthritis.

Key words: rheumatoid arthritis, synovial membrane, arthroscopy, spironolactone.

REFERENCES

1. Hitchon C.A., El-Gabalawy H.S. The synovium in rheumatoid arthritis. Open Rheumatol. J, 2011, vol. 5, pp. 107-114.
2. Klint E., Catrina A.I., Matt P. et al. Evaluation of arthroscopy and macroscopic scoring. Arthritis Research & Therapy, 2009, vol. 11, pp. 714.
3. Lyalina V.V., Shekhter A.B. Artroskopiya i morfologiya sinovitov [Arthroscopy and morphology of synovitis]. Moscow: Nauka, 2007. 108 p.
4. Bunda S., Wang Y., Mitts T.F. et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase. Akt. J. Biol. Chem, 2009, vol. 284(24), pp. 16633-47.
5. Ulrik S.S., Sønder S., Mikkelsen M. et al. Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br. J. Pharmacol, 2006, vol. 148(1), pp. 46-53.
6. Savoia C., Touyz R.M., Amiri F., Schiffrin E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension, 2008, vol. 51, pp. 432-439.
7. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med, 1999, vol. 341, pp. 709-717.
8. Fiebeler A. Muller D.N., Shagdarsuren E., Luft F.C. Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens, 2007, vol. 16(2), pp. 134-42.
9. Huang L.L., Nikolic-Paterson D.J., Ma F.Y., Tesch G.H. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signaling. Nephron. Exp. Nephrol, 2012, vol. 120(4), pp. 115-122.
10. Seredyuk V. Role of Aldosterone, Mitogenic Growth Factors, Apoptosis Inducers and Pulmonary Arterial Hypertension in the Formation and Progression of Chronic Pulmonary Heart Disease. The Pharma Innovation Journal, 2013, vol. 2(5), pp. 36-40.
11. Bagriy A.E. Place of aldosterone antagonists in the treatment of cardiovascular disease: Today and Tomorrow. Novosti meditsiny i farmatsii. Kardiologiya, 2010, no. 338 (in Russ.).